Comparison Between 2 Techniques for Bilateral Salpingectomy

NCT ID: NCT03788421

Last Updated: 2022-03-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

51 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-01

Study Completion Date

2021-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A comparison between 2 techniques for bilateral salpingectomy during cesarean section.

Primary outcomes are total operative time and bilateral completion of the randomized procedure. Secondary outcomes included surgical complications and post operation complications.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ovarian cancer is the most lethal gynecologic malignancy. Major contributors to this high mortality are the lack of effective screening strategies, diagnosis at advanced stage of presentation as well as the high risk of recurrence. In the last years the Gynecologic Associations worldwide have recommended that total salpingectomy be considered for potential ovarian cancer risk reduction in benign gynecologic surgeries after completion of childbearing.

However, the data are limit regarding the Preferred surgical technique during cesarean section.

In this randomized controled trial the investigators will compare between various techniques for bilateral salpingectomy during cesarean section.

Primary outcomes are total operative time and bilateral completion of the randomized procedure. Secondary outcomes included surgical complications and post operation complications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sterility, Female

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study group

Women undergoing elective bilateral salpingectomy during cesarean section with LIGASURE.

Group Type ACTIVE_COMPARATOR

LIGASURE

Intervention Type DEVICE

Electricity based cautery tool used during both laparoscopic and open surgery for optimal hemostasis.

Control group

Women undergoing elective bilateral salpingectomy during cesarean section with traditional step by step clamping and suturing.

Group Type ACTIVE_COMPARATOR

Clamping and suturing

Intervention Type PROCEDURE

Step by step clamping and suturing of the mesosalpinx until achievement of total salpingectomy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LIGASURE

Electricity based cautery tool used during both laparoscopic and open surgery for optimal hemostasis.

Intervention Type DEVICE

Clamping and suturing

Step by step clamping and suturing of the mesosalpinx until achievement of total salpingectomy.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants undergoing elective Cesarean Section and are interested and have signed informed consent regarding bilateral salpingectomy.

Exclusion Criteria

* Inability to give informed consent.
* Preterm delivery (\< 37 weeks' gestation).
* Fetal demise.
* Prenatal diagnosis of fetal or placental abnormalities.
* Previous tubal surgery.
* The use of anticoagulants.
* Associated immunosuppressive conditions.
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rambam Health Care Campus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yaniv Zipori MD

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yaniv Zipori, MD

Role: PRINCIPAL_INVESTIGATOR

Rambam healthcare campus

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rambam health care campus

Haifa, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0427 - 18 - RMB

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

LESS-TLH Versus LESS-LAVH
NCT01861067 COMPLETED PHASE3